Anika Therapeutics ANIK Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$11.36M-1.6% | -$11.17M+66.2% | -$33.04M+45.5% | -$60.63M-6.8% | -$56.74M-0.6% | ||
| $5.4M+0.4% | $5.37M-4.3% | $5.61M-7.7% | $6.08M-6.9% | $6.53M-5.1% | ||
| $13.86M+37.5% | $10.08M+2.1% | $9.88M-10.7% | $11.06M-10.8% | $12.4M-5.5% | ||
| $83K+1,286% | -$7K-103% | $252K— | —— | —— | ||
| —— | —— | -$1.81M+23.2% | -$2.36M+8.0% | -$2.56M+10.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $740K+1,662% | $42K+104% | -$956K+76.8% | -$4.12M-44.1% | -$2.86M-14.1% | ||
| —— | —— | —— | —— | —— | ||
| -$802K+65.5% | -$2.33M-117% | -$1.07M— | —— | —— | ||
| —— | —— | -$372K-142% | $888K+58.0% | $562K-15.5% | ||
| $1.95M-5.5% | $2.06M-4.2% | $2.15M-4.1% | $2.24M+3.7% | $2.16M+0.6% | ||
| $6.47M-42.2% | $11.19M+37.6% | $8.13M+29.5% | $6.28M+16.3% | $5.4M-0.1% | ||
| $5.43M-20.4% | $6.83M-8.8% | $7.49M+9.8% | $6.81M-22.1% | $8.75M+13.1% | ||
| —— | —— | —— | —— | $4.5M— | ||
| —— | —— | —— | —— | -$4.85M+41.8% | ||
| —— | —— | —— | —— | $14.89M+36.4% | ||
| $1.76M+12.1% | $1.57M-4.4% | $1.64M-0.5% | $1.65M-6.9% | $1.77M-31.9% | ||
| -$15.64M-45.8% | -$10.73M+0.7% | -$10.81M+26.9% | -$14.78M+7.0% | -$15.89M-24.9% | ||
| —— | —— | —— | $660K+625% | $91K+290% | ||
| —— | —— | -$4.38M+54.7% | -$9.66M+36.7% | -$15.26M+2.9% | ||
| —— | $1.08M-40.4% | $1.81M-28.8% | $2.53M-22.3% | $3.26M-18.3% | ||
| —— | —— | —— | —— | —— | ||
| -$802K+65.5% | -$2.33M-117% | -$1.07M— | —— | —— | ||
| $6.02M+3.4% | $5.82M-75.3% | $23.6M-48.5% | $45.81M+5.4% | $43.48M-2.8% | ||
| $1.95M-5.5% | $2.06M-4.2% | $2.15M-4.1% | $2.24M+3.7% | $2.16M+0.6% | ||
| $1.52M+14.4% | $1.33M+175% | $483K+47.3% | $328K— | —— | ||
| —— | —— | —— | —— | $4.5M— | ||
| $148K-58.5% | $357K-41.4% | $609K-34.2% | $925K-17.2% | $1.12M-9.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $660K+625% | $91K+290% | ||
| -$1.9M+5.1% | -$2M+5.0% | -$2.1M+4.0% | -$2.19M-4.0% | -$2.11M-1.1% | ||
| $851K-5.0% | $896K+111% | $424K+22.9% | $345K+54.0% | $224K— | ||
| —— | $0-100% | $1.48M-50.0% | $2.97M-33.3% | $4.45M-25.0% | ||
| $587K+122% | $265K-28.6% | $371K-69.5% | $1.22M+62.9% | $746K-37.0% | ||
| —— | $1.08M-40.4% | $1.81M-28.8% | $2.53M-22.3% | $3.26M-18.3% | ||
| $1.04M-76.2% | $4.36M— | —— | —— | —— | ||
| $1.04M-76.2% | $4.36M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Anika Therapeutics generate?
- Anika Therapeutics (ANIK) generated $6.5M in operating cash flow over the trailing twelve months.
- What is Anika Therapeutics's free cash flow?
- After $5.4M of capital expenditures, Anika Therapeutics's free cash flow was $1.0M over the trailing twelve months, up 105.4% year over year.
- Where does Anika Therapeutics's cash flow data come from?
- Every line is extracted from Anika Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
